Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Y-mAbs Therapeutics, Inc. (YMAB)
|
|
| Balance Sheet |
|
|
|
| Standardized | As Reported |
Annual | Quarterly |
|
| In millions, except per share items | Jun-30-23 | Mar-31-23 | Dec-31-22 | Sep-30-22 | Jun-30-22 | Mar-31-22 | Dec-31-21 | Sep-30-21 |
| | 10-Q | 10-Q | | 10-Q | 10-Q | 10-Q | 10-K | 10-Q |
| Assets |
| Cash and equivalents | 87.9 | 92.6 | | 114.5 | 133.7 | 156.7 | 181.6 | 215.7 |
| Accounts receivable, net | 19.1 | 18.7 | | 9.3 | 7.2 | 9.3 | 7.7 | 7.3 |
| Inventories | 5.2 | 8.9 | | 6.2 | 6.8 | 5.6 | 5.5 | 4.8 |
| Other current assets | 3.6 | 3.7 | | 3.2 | 6.3 | 6.1 | 7.5 | 2.8 |
| Total current assets | 115.8 | 124.0 | | 133.2 | 153.9 | 177.7 | 202.3 | 230.6 |
| Property, plant, and equipment, net | 0.4 | 0.5 | | 1.4 | 1.6 | 1.7 | 1.8 | 1.8 |
| Intangibles | 2.8 | 2.9 | | 1.5 | 1.6 | 1.6 | 1.7 | |
| Other fixed assets | 12.3 | 8.7 | | 5.6 | 5.7 | 6.8 | 3.2 | 4.8 |
| Total assets | 132.4 | 137.4 | | 143.9 | 165.2 | 191.0 | 212.8 | 240.0 |
| |
| Accounts payable | 7.3 | 8.8 | | 13.7 | 11.3 | 14.7 | 13.6 | 11.0 |
| Accrued expenses | 16.2 | 16.2 | | 17.1 | 17.1 | 12.9 | 12.5 | 12.5 |
| Short-term debt | 0.0 | 0.0 | | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Other current liabilities | 0.8 | 0.9 | | 1.2 | 1.1 | 1.5 | 1.8 | 1.8 |
| Total current liabilities | 24.2 | 25.9 | | 32.0 | 29.5 | 29.0 | 27.9 | 25.4 |
| Other liabilities | 3.5 | 3.7 | | 4.0 | 4.3 | 4.5 | 4.8 | 3.8 |
| Total liabilities | 27.7 | 29.6 | | 36.0 | 33.8 | 33.6 | 32.7 | 29.1 |
| |
| Shareholders' equity [+] | 104.7 | 107.8 | | 107.9 | 131.4 | 157.5 | 180.1 | 210.8 |
| Paid-in capital | 552.4 | 549.2 | | 540.4 | 538.0 | 524.3 | 519.2 | 514.2 |
| Retained earnings | -448.7 | -442.4 | | -437.2 | -409.7 | -368.5 | -340.5 | -303.6 |
| Tangible shareholders' equity | 101.9 | 104.9 | | 106.4 | 129.8 | 155.9 | 178.4 | 210.8 |
|